Abstract: The present invention aims to provide a scintillator which has a short fluorescence decay time, whose fluorescence intensity after a period of time following radiation irradiation is low, and which shows largely improved light-transmittance. A scintillator represented by the following General Formula (1), the scintillator including Zr, having a Zr content of not less than 1500 ppm by mass therein, and being a block of a sintered body. QxMyO3z:A . . . (1) (wherein in General Formula (1), Q includes at least one or more kinds of divalent metallic elements; M includes at least Hf; and x, y, and z independently satisfy 0.5?x?1.5, 0.5?y?1.5, and 0.7?z?1.5, respectively).

Abstract: The present invention aims to provide a scintillator which has a short fluorescence decay time, whose fluorescence intensity after a period of time following radiation irradiation is low, and which shows largely improved light-transmittance. A scintillator represented by the following General Formula (1), the scintillator including Zr, having a Zr content of not less than 1500 ppm by mass therein, and being a block of a sintered body. QxMyO3z:A . . . (1) (wherein in General Formula (1), Q includes at least one or more kinds of divalent metallic elements; M includes at least Hf; and x, y, and z independently satisfy 0.5?x?1.5, 0.5?y?1.5, and 0.7?z?1.5, respectively).

Abstract: A computer of an ordering supporting server executes: a process of acquiring information necessary for specifying a product model number corresponding to a specific product from a terminal apparatus; a process of specifying a product model number corresponding to the specific product on the basis of the acquired information; a process of specifying, on the basis of constituent component data associated with the specific product, a component model number associated with the product model number while defining a value of a component variable part associated with a value of a variable part of the product model number according to a rule for an associated relation set between the model numbers; and a process of providing the specified component identification information to the terminal apparatus.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.

Abstract: A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.

Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.

Abstract: Provided is a scintillator for neutrons that allows the detection of neutrons with superb sensitivity and that is little affected by background noise derived from ?-rays, and a neutron detector that uses the neutron scintillator. The scintillator for neutrons comprises borate that contains at least Mg and a divalent transition element.

Abstract: Provided is a scintillator for neutrons that allows the detection of neutrons with superb sensitivity and that is little affected by background noise derived from ?-rays, and a neutron detector that uses the neutron scintillator. The scintillator for neutrons comprises borate that contains at least Mg and a divalent transition element.

Abstract: The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration.

Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.

Abstract: A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.

Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.

Abstract: A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.